| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 08/02/2001 | CA2398561A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | CA2398548A1 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398396A1 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398288A1 Ibuprofen containing active agent preparation |
| 08/02/2001 | CA2398003A1 Phosphodiesterases |
| 08/02/2001 | CA2397831A1 Enhanced propertied pharmaceuticals |
| 08/02/2001 | CA2397758A1 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate |
| 08/02/2001 | CA2397493A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | CA2396640A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | CA2396596A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/01/2001 | EP1120114A2 Compositions and methods for treating conditions responsive to estrogen |
| 08/01/2001 | EP1119643A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-$g(a) (TNF-$g(a)) EXPRESSION |
| 08/01/2001 | EP1119629A2 Oxidoreductase molecules |
| 08/01/2001 | EP1119620A2 Polynucleotides coding for secreted polypeptides. some having similarity to syncollin or claudin or cytokine. their therapeutic uses |
| 08/01/2001 | EP1119580A1 ANTISENSE MODULATION OF EXPRESSION OF TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTORS (TRAFs) |
| 08/01/2001 | EP1119568A1 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| 08/01/2001 | EP1119567A1 Quinazoline derivatives |
| 08/01/2001 | EP1119555A1 Biphenylene lactams as prostaglandin receptor ligands |
| 08/01/2001 | EP1119551A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119543A1 N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor |
| 08/01/2001 | EP1119542A1 Prostaglandin receptor ligands |
| 08/01/2001 | EP1119362A1 Method of using tetracycline compounds to enhance interleukin-10 production |
| 08/01/2001 | EP1119357A1 C3a receptor ligands |
| 08/01/2001 | EP1119355A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119354A1 Peripherally acting anti-pruritic opiates |
| 08/01/2001 | EP1119353A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
| 08/01/2001 | EP1119253A1 NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF |
| 08/01/2001 | EP0975350B1 Use of an extract of alchemilla vulgaris |
| 08/01/2001 | EP0877737B1 Novel n-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity |
| 08/01/2001 | EP0862567B1 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists |
| 08/01/2001 | EP0737074B1 Botulinum toxins for treating hyperhydrosis |
| 08/01/2001 | CN1306576A G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 08/01/2001 | CN1306526A Novel heterocyclically substituted amides with cysteine protease-inhibiting effect |
| 08/01/2001 | CN1306512A Heterocyclic inhibitors of P38 |
| 08/01/2001 | CN1306509A Substituted benzamides, their prodn. and use as cysteine protease inhibitors |
| 08/01/2001 | CN1306508A Hydroxamic acid derivatives as inhibitors or prodn. of human CD23 and of TNF release |
| 08/01/2001 | CN1306505A Substituted benzamides, their prodn. and use |
| 08/01/2001 | CN1306433A Use of chemically-stabilized chlorite solution for inhibiting antigen-specific immune response |
| 08/01/2001 | CN1306428A Inhibitors of transcription factor NF-KB |
| 08/01/2001 | CN1306425A Process for synthesizing Cox-2 inhibitors |
| 08/01/2001 | CN1306424A Utilization of aryl (or heteroaryl) azolylcarbinol derivatives in prepn. of medicament for treatment of neurogenic inflammation |
| 08/01/2001 | CN1305993A Cyclic guanyl preparation used as nitrogen oxide synthetic enzyme inhibitor |
| 07/31/2001 | US6268477 Amino acid sequence; detection and treatment of atherosclerosis, rheumatoid arthritis, asthma, aids (acquired immune deficiency syndrome); viricides; antiinflammatory agents; antitumor agents; antiarthritic agents |
| 07/31/2001 | US6268391 Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases |
| 07/31/2001 | US6268387 Inhibitors of the enzyme 15-lipoxygenase and are inhibitors of monocyte chemotaxis. |
| 07/31/2001 | US6268379 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 07/31/2001 | US6268365 Src family SH2 domain inhibitors |
| 07/31/2001 | US6268355 Stable aspirin-containing preparations for external use |
| 07/31/2001 | US6268346 Having high biological activity of the same type as the known natural compound bpc, but with shorter amino acid chains. |
| 07/31/2001 | US6268341 These polypeptides are useful for treating diseases wherein antagonism of hupar is therapeutically beneficial. |
| 07/31/2001 | US6268151 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/31/2001 | US6267945 Farnesol-related calcium channel blockers |
| 07/31/2001 | CA2218372C Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds |
| 07/31/2001 | CA2068763C Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| 07/31/2001 | CA2041240C Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
| 07/31/2001 | CA2035951C Bilobalide derivatives, their applications and formulations containing them |
| 07/31/2001 | CA1341276C Hyaluronic acid esters and salts |
| 07/26/2001 | WO2001053530A1 Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | WO2001053468A2 Lipid metabolism enzymes and polynucleotides encoding them |
| 07/26/2001 | WO2001053353A2 Recombinant antibodies to human interkleukin-1 beta |
| 07/26/2001 | WO2001053344A2 Chondromodulin-i related peptide |
| 07/26/2001 | WO2001053343A1 Human polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | WO2001053330A2 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them |
| 07/26/2001 | WO2001053317A1 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/26/2001 | WO2001053311A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression |
| 07/26/2001 | WO2001053297A1 Alpha v integrin receptor antagonists |
| 07/26/2001 | WO2001053295A1 Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin |
| 07/26/2001 | WO2001053294A1 Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |
| 07/26/2001 | WO2001053291A1 Benzimidazole derivatives |
| 07/26/2001 | WO2001053285A1 Food product and process |
| 07/26/2001 | WO2001053279A1 Urea compounds as inhibitors for vla-4 |
| 07/26/2001 | WO2001053272A1 Human chymase inhibitors |
| 07/26/2001 | WO2001053271A1 Imidazole compounds and their use as adenosine deaminase inhibitors |
| 07/26/2001 | WO2001053266A1 Therapeutic morpholino-substituted compounds |
| 07/26/2001 | WO2001053263A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | WO2001053261A1 Substituted glutarimides and use thereof il-12 production inhibitors |
| 07/26/2001 | WO2001052892A2 Jak/stat pathway inhibitors and the uses thereof |
| 07/26/2001 | WO2001052885A1 Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins |
| 07/26/2001 | WO2001052863A1 Antisense modulation of mekk2 expression |
| 07/26/2001 | WO2001052847A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 07/26/2001 | WO2001052841A1 Decursinol or derivative thereof as analgesic agent |
| 07/26/2001 | WO2001052825A2 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 07/26/2001 | WO2001052809A1 Cosmetic and/or pharmaceutical preparations containing an active quantity of an arrabidaea chica extract |
| 07/26/2001 | WO2001052664A1 Immune modulation with death receptor-induced apoptosis |
| 07/26/2001 | WO2001052651A2 Particulate blends and compacted products formed therefrom, and the preparation thereof |
| 07/26/2001 | WO2001046180A8 Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same |
| 07/26/2001 | WO2001014886A3 Inhibitors of binding between proteins and macromolecular ligands |
| 07/26/2001 | WO2001001748A3 Peptide compounds that bind her2 |
| 07/26/2001 | WO2000070341A3 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 07/26/2001 | WO2000066156A8 Death domain containing receptor 5 |
| 07/26/2001 | WO2000041566A9 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 07/26/2001 | WO2000017361A3 Interferon-epsilon |
| 07/26/2001 | US20010009921 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 07/26/2001 | US20010009917 Reducing associated adverse effects; 5-lipoxygenase inhibitor, useful in treatment of conditions related to elevated leukotriene levels |
| 07/26/2001 | US20010009899 Process for the preparation of pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects |
| 07/26/2001 | DE10037590A1 Natural plant disinfectant and its preparation |
| 07/26/2001 | DE10002509A1 New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
| 07/26/2001 | CA2743326A1 High purity lipopeptides, lipopeptide micelles and processes for preparing same |
| 07/26/2001 | CA2673615A1 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |